Highlights
- •All women with ovarian cancer offered genetic testing by their gynecologic oncologist underwent testing.
- •Only 67% of those undergoing standard of care pretest counseling underwent genetic testing.
- •Time to test result was faster when the gynecologic oncologists ordered genetic testing than standard care.
- •Patients, providers and genetic counselors reported high satisfaction with point of care genetic testing.
Abstract
Objective
Referral to Genetics for pre-testing counseling may be inefficient for women with
ovarian cancer. This study assesses feasibility of gynecologic oncologists directly
offering genetic testing.
Methods
A prospective pilot study was conducted at two gynecologic oncology hubs in an integrated
healthcare system from May 1 to November 6, 2019. Gynecologic oncologists offered
multigene panel testing to women with newly diagnosed ovarian cancer, followed by
selective genetic counseling. Outcomes were compared between study participants and
women from other hubs in the health system.
Results
Of ovarian cancer patients at study sites, 40 participated and all underwent genetic
testing. Of 101 patients diagnosed at other sites, 85% were referred to genetics (p = .0061 compared to pilot participants) and 67% completed testing (p < .0001). The time from diagnosis to blood draw and notification of result was 18.5
and 34 days for the pilot group compared to 25.5 and 53 days at other sites. Panel
testing detected 9 (22.5%) and 7 (10.3%, p = .08) pathogenic mutations in each group, respectively. Patients and providers were
highly satisfied with the streamlined process.
Conclusion
Genetic testing performed at the gynecologic oncology point of care for patients with
ovarian cancer is feasible, increases uptake of testing, and improves time to results.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Genetic testing: what problem are we trying to solve?.J Clin Oncol. 2017; 35 (PubMed PMID: 28820645): 3789-3791
- DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP).www.genome.gov/sequencingcostsdataDate accessed: May 11, 2020
- Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?.J Clin Oncol. 2013; 31 (PubMed PMID: 23460708): 1267-1270
- Multigene panel testing in oncology practice: how should we respond?.JAMA Oncol. 2015; 1 (PubMed PMID: 26181167): 277-278
- A cost analysis of a cancer genetic service model in the UK.J Community Genet. 2016; 7 (PubMed PMID: 26922077; PMCID: PMC4960025): 185-194
- Development of cancer genetic services in the UK: A national consultation.Genome Med. 2015; 7 (PubMed PMID: 25722743; PMCID: PMC4341881): 18
- Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Clin Cancer Res. 2014; 20 (PubMed PMID: 24240112; PMCID: PMC3944197): 764-775
- BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.J Clin Oncol. 2012; 30 (PubMed PMID: 22711857; PMCID: PMC3413277): 2654-2663
- Olaparib plus bevacizumab as first-line maintenance in ovarian cancer.N Engl J Med. 2019; 381 (PubMed PMID: 31851799): 2416-2428
- Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer.N Engl J Med. 2019; 381 (PubMed PMID: 31562800; PMCID: PMC6941439): 2403-2415
- Niraparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med. 2019; 381 (PubMed PMID: 31562799): 2391-2402
- Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.N Engl J Med. 2016; 375 (PubMed PMID: 27717299): 2154-2164
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2017; 18 (PubMed PMID: 28754483): 1274-1284
- Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med. 2018; 379 (PubMed PMID: 30345884): 2495-2505
- National estimates of genetic testing in women with a history of breast or ovarian cancer.J Clin Oncol. 2017; 35 (PubMed PMID: 28820644; PMCID: PMC5707208): 3800-3806
- Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities.Obstet Gynecol. 2010; 115 (PubMed PMID: 20410767; PMCID: PMC5295824): 945-952
- Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?.Int J Gynecol Cancer. 2013; 23 (PubMed PMID: 23354368): 431-436
- Disparities in genetics assessment for women with ovarian cancer: can we do better?.Gynecol Oncol. 2018; 149 (PubMed PMID: 29605055): 84-88
- Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.Sci Rep. 2016; 6 (PubMed PMID: 27406733; PMCID: PMC4942815): 29506
- A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.Med Care. 2009; 47 (PubMed PMID: 19433995): 626-633
- A brief assessment of concerns associated with genetic testing for cancer: the multidimensional impact of cancer risk assessment (MICRA) questionnaire.Health Psychol. 2002; 21 (PubMed PMID: 12433008): 564-572
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2020.https://www.nccn.org/Date accessed: May 8, 2020
- Force USPST. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. preventive services task force recommendation statement.Ann Intern Med. 2014; 160 (PubMed PMID: 24366376): 271-281
- Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.Gynecol Oncol. 2015; 138 (PubMed PMID: 25933682; PMCID: PMC4868086): 109-114
- Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer.J Clin Oncol. 2016; 34 (PubMed PMID: 27161971; PMCID: PMC5012689 online at www.jco.org. Author contributions are found at the end of this article): 2610-2618
- American Board of Genetic Counseling: Practice Analysis and Information.https://www.abgc.net/for-diplomates/practice-analysis.aspx/Date accessed: May 8, 2020
- Use of BRCA mutation test in the U.S., 2004–2014.Am J Prev Med. 2017; 52 (PubMed PMID: 28342662; PMCID: PMC5370584): 702-709
- Impact of payer constraints on access to genetic testing.J Oncol Pract. 2017; 13 (PubMed PMID: 28084878): e47-e56
- Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer.J Clin Oncol. 2018; 36 (PubMed PMID: 29558274; PMCID: PMC6804908): 1300-1307
- Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer.J Clin Oncol. 2017; 35 (PubMed PMID: 28402748; PMCID: PMC5501363): 2232-2239
- Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations.Genet Med. 2014; 16 (PubMed PMID: 24854227): 896-902
Article info
Publication history
Published online: August 07, 2020
Accepted:
July 18,
2020
Received:
June 3,
2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
